The “left field but logical” buy sees Sanofi gaining a graft-versus-host disease therapy to add to its transplant offering.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.